|
|
Details: |
|
|
Develops pharmaceuticals relating to anti-cancer therapeutics. Includes product portfolio, with clinical trials and licensing details, conferences, international careers from San Antonio, Texas. (Nasdaq: ILXO).
|
URL: |
http://www.ilexonc.com/
|
Title: |
Genzyme Oncology |
Image: |
|
Description: |
Business, Biotechnology and Pharmaceuticals, Cancer Research - Ilex Oncology, Inc.. Develops pharmaceuticals relating to anti-cancer therapeutics. |
Similar: |
|
|
|
Related Sites |
|
Molecular Diagnostics Inc. (Popularity: ): Engaged in the design, development and commercialization of tumor screening systems. Information for investors, clinicians and patients, about their technologies, ...
CancerVax Corp. (Popularity: ): Development and commercialization of vaccines, and treatments, such as telomere homologs and angiogenesis inhibition. Includes product pipeline, clinical trials, corporate ...
Geron Corporation (Popularity: ): Discovers and develops therapeutic and diagnostic products, as well as stem cell projects for skin aging, atherosclerosis, osteoporosis and macular ...
Genentech Biooncology (Popularity: ): Resource treatments aimed at chronic management, focusing on anti-angiogenesis, apoptosis, B-cell biology and HER signaling. Includes sections for professionals, customers ...
Boston Life Sciences, Inc. (Popularity: ): Researches and develops novel therapeutic and diagnostic products to treat chronic debilitating diseases such as cancer, central nervous system disorders ...
Heal Corporation (Popularity: ): Details of projects using resistance related to polyunsaturated fatty acids and catalase in vitro, applied in vivo to trout model. ...
|
|
Popular Sites |
|
Heal Corporation (Popularity: ): Details of projects using resistance related to polyunsaturated fatty acids and catalase in vitro, applied in vivo to trout model. ...
Boston Life Sciences, Inc. (Popularity: ): Researches and develops novel therapeutic and diagnostic products to treat chronic debilitating diseases such as cancer, central nervous system disorders ...
Genentech Biooncology (Popularity: ): Resource treatments aimed at chronic management, focusing on anti-angiogenesis, apoptosis, B-cell biology and HER signaling. Includes sections for professionals, customers ...
Geron Corporation (Popularity: ): Discovers and develops therapeutic and diagnostic products, as well as stem cell projects for skin aging, atherosclerosis, osteoporosis and macular ...
CancerVax Corp. (Popularity: ): Development and commercialization of vaccines, and treatments, such as telomere homologs and angiogenesis inhibition. Includes product pipeline, clinical trials, corporate ...
|
|
Related Press |
|
Chiltern Welcomes Gastroenterology, Oncology and Pediatric Therapeutic Experts to Their Team (Popularity: ): LONDON, Jan. 31, 2012 -- Chiltern International Limited (Chiltern), a global contract research organization (CRO), announced that Drs. Marcelo Piccirillo ...
Study Evaluating Novel Combination of nab-paclitaxel and capecitabine for 1st Line Treatment of Metastatic Breast Cancer Presented at the American Society of Clinical Oncology Annual Meeting (Popularity: ): Researchers from The West Clinic, the Mid-South's premier provider of interdisciplinary cancer care, and ACORN (Accelerated Community Oncology Research Network) ...
Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway (Popularity: ): Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Aurigene Discovery ...
FDA Expands Use of Approved Breast Cancer Drug (Popularity: ): The U.S. Food and Drug Administration today approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and ...
'My Child Matters' Program One-Year Report Shows Measurable Improvement in Cancer Care for Children in Developing and Newly Industrialized Countries (Popularity: ): According to a report released today at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO), the ...
|
|
Related Articles |
|
|
|
|